News
SHPHF
0.210
NaN%
--
Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of Anaprazole
TipRanks · 1d ago
Sihuan Pharmaceutical Shareholders Approve All AGM Resolutions and Capital Mandates
TipRanks · 5d ago
Sihuan’s Xuanzhu Biopharm Launches Phase III Trial for Anaprazole in H. pylori Therapy
TipRanks · 06/22 04:07
Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Surges
TipRanks · 06/08 12:12
Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Drives Profitable Growth
TipRanks · 06/03 12:08
Sihuan Pharmaceutical Sets 2026 AGM to Approve FY2025 Results, Dividend and Share Issuance Mandate
TipRanks · 06/02 08:39
Sihuan Pharmaceutical Holdings Group (SHPHF) Receives a Buy from Guotai Haitong
TipRanks · 06/02 05:18
Sihuan Pharmaceutical Forms AI-Driven Medical Aesthetics JV with dProtein
TipRanks · 05/28 08:40
Sihuan Pharma Buys Shares for Award Scheme as Medical Aesthetics Drives Profit Turnaround
TipRanks · 05/27 13:47
Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit
TipRanks · 05/18 13:10
Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges
TipRanks · 05/13 11:21
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
TipRanks · 05/12 09:40
Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma
TipRanks · 04/21 11:00
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
TipRanks · 04/20 09:09
Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
TipRanks · 04/20 04:08
Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation
TipRanks · 04/17 11:09
Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori
TipRanks · 04/15 04:08
Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion
TipRanks · 04/12 10:37
Sihuan Pharmaceutical Holdings Group (SHPHF) Gets a Buy from Citic Securities
TipRanks · 04/10 00:56
Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets
TipRanks · 04/09 09:15
More
Webull provides a variety of real-time SHPHF stock news. You can receive the latest news about Sihuan Pharm Hld through multiple platforms. This information may help you make smarter investment decisions.
About SHPHF
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.